Q-omics provides the consensus-scored UQCC1 profile across patient tissues and cancer cell-line models. UQCC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, UQCC1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, UQCC1 RNA expression shows 20,077 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where UQCC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UQCC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UQCC1 survival associations across molecular data types. UQCC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UQCC1 RNA expression–survival associations across cancer types. High UQCC1 expression shows unfavorable associations in UVM, LGG, LIHC, ACC and OV, but favorable associations in READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for UQCC1 RNA expression.
This table summarizes UQCC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UQCC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UQCC1 shows lower tumor expression in THCA and higher tumor expression in STAD, LIHC, COAD, LUAD and READ. The THCA box plot shows higher UQCC1 RNA expression in normal versus tumor tissue (log2 FC = −0.750, t-test p < 0.001).
This table shows molecular features associated with UQCC1 in patient tissues and cancer cell lines. In patient samples, UQCC1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UQCC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and PANCREAS.
